Know How COVID-19 Oral Antivirals Compare
February 2022
You'll start to see the new COVID-19 oral antivirals, nirmatrelvir/ritonavir (Paxlovid) and molnupiravir.
Either is an option for outpatients with COVID-19 who are at high risk of developing serious illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
They're started within 5 days of symptoms...and patients don't currently have to pay for these meds.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote